Xeris Biopharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2016
Revenue	203.07	163.91	110.25	49.59	20.44	Upgrade
Revenue Growth (YoY)	23.89%	48.68%	122.32%	142.67%	650.74%	Upgrade
Cost of Revenue	36.83	28.65	22.63	13.32	9.33	Upgrade
Gross Profit	166.24	135.27	87.61	36.27	11.11	Upgrade
Selling, General & Admin	157.38	146.1	137.75	116.06	73.73	Upgrade
Research & Development	25.56	22.34	20.97	25.16	18.92	Upgrade
Operating Expenses	193.78	179.28	169.55	141.77	92.65	Upgrade
Operating Income	-27.55	-44.01	-81.94	-105.5	-81.55	Upgrade
Interest Expense	-30.49	-26.61	-14.1	-7.18	-10.66	Upgrade
Interest & Investment Income	5.32	4.75	2.58	0.73	1.47	Upgrade
Other Non Operating Income (Expenses)	0.01	0	1.76	-0.7	-0.01	Upgrade
EBT Excluding Unusual Items	-52.7	-65.87	-91.7	-112.66	-90.75	Upgrade
Merger & Restructuring Charges	-	-	-	-9.66	-2	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-0.41	-	Upgrade
Legal Settlements	-	-	-	-	1.5	Upgrade
Other Unusual Items	-4.4	2.36	-4.38	-	-	Upgrade
Pretax Income	-57.1	-63.5	-96.08	-122.73	-91.25	Upgrade
Income Tax Expense	-2.27	-1.25	-1.42	-	-0.11	Upgrade
Net Income	-54.84	-62.26	-94.66	-122.73	-91.14	Upgrade
Net Income to Common	-54.84	-62.26	-94.66	-122.73	-91.14	Upgrade
Shares Outstanding (Basic)	147	138	136	79	43	Upgrade
Shares Outstanding (Diluted)	147	138	136	79	43	Upgrade
Shares Change (YoY)	6.61%	1.51%	71.62%	85.32%	63.32%	Upgrade
EPS (Basic)	-0.37	-0.45	-0.70	-1.55	-2.14	Upgrade
EPS (Diluted)	-0.37	-0.45	-0.70	-1.55	-2.14	Upgrade
Free Cash Flow	-37.85	-49.29	-103.42	-96.62	-80.94	Upgrade
Free Cash Flow Per Share	-0.26	-0.36	-0.76	-1.22	-1.90	Upgrade
Gross Margin	81.86%	82.52%	79.47%	73.14%	54.35%	Upgrade
Operating Margin	-13.56%	-26.85%	-74.32%	-212.74%	-399.05%	Upgrade
Profit Margin	-27.00%	-37.98%	-85.86%	-247.48%	-446.00%	Upgrade
Free Cash Flow Margin	-18.64%	-30.07%	-93.80%	-194.84%	-396.06%	Upgrade
EBITDA	-15.48	-31.68	-69.7	-103.62	-80.08	Upgrade
EBITDA Margin	-7.62%	-19.33%	-63.22%	-208.95%	-	Upgrade
D&A For EBITDA	12.07	12.33	12.24	1.88	1.47	Upgrade
EBIT	-27.55	-44.01	-81.94	-105.5	-81.55	Upgrade
EBIT Margin	-13.56%	-26.85%	-74.32%	-212.74%	-	Upgrade
Revenue as Reported	203.07	163.91	110.25	49.59	20.44	Upgrade

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q